Use of tab2 in the diagnosis and treatment of parkinson's disease
By using TAB2 inhibitors such as siRNA and shRNA to reduce TAB2 levels, the problem of Parkinson's disease progression was solved, enabling effective diagnosis and treatment of PD and improving motor function in PD mice.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BEIJING NEUROSURGICAL INST
- Filing Date
- 2025-10-22
- Publication Date
- 2026-06-05
AI Technical Summary
There is a lack of effective methods to stop the progression of Parkinson's disease in the current technology. Existing treatments have serious adverse reactions after long-term use, and there are no effective therapies to slow the course of the disease.
Inhibitors of TAB2, such as siRNA, shRNA, ribozymes, and antisense oligonucleotides, are used to prepare drugs for treating Parkinson's disease, which block disease progression by lowering TAB2 levels. Reagents for detecting TAB2 levels are also provided for diagnosis.
In animal and cell models of PD, inhibition of TAB2 reduced apoptosis-related proteins in neurons and improved motor function in PD mice, providing an effective direction for diagnosis and treatment.
Smart Images

Figure CN121313838B_ABST
Abstract
Citation Information
Patent Citations
Applications of LOC105373420 in diagnosis and treatment of Parkinson's disease
CN108103185A
Biomarker for diagnosing Parkinson's disease and application thereof
CN117630375A